Brief: Tvardi Therapeutics' update on Phase 2 Revert trial in Idiopathic Pulmonary Fibrosis
13/10/2025 12:36
Oct 13 (Reuters) - Tvardi Therapeutics Inc TVRD.O: TVARDI THERAPEUTICS PROVIDES UPDATE ON PRELIMINARY DATA FROM PHASE 2 REVERT TRIAL IN IDIOPATHIC PULMONARY FIBROSIS TVARDI THERAPEUTICS INC - STUDY DID NOT MEET ITS GOALS Source text: ID:nBw1P2Jr2a Further company coverage: TVRD.O (Reporting by Anhata Rooprai) ((Anhata.Rooprai@thomsonreuters.com;))
Recent news on Tvardi Therapeutics
See all newsTvardi Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Tvardi Therapeutics Q2 net loss slightly lower estimates
Brief: Tvardi Therapeutics Inc Q2 Net Income USD -6.5 Million Vs. IBES Estimate USD -6.54 Million
Tvardi Therapeutics, Inc. expected to post a loss of 70 cents a share - Earnings Preview
NASDAQ RESUMED AT 07:50 PM